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ABSTRACT
Glioblastoma multiforme (GBM) is the most common and aggressive type 
of malignant glioma. Oncolytic adenoviruses are being modified to exploit the 
aberrant expression of proteins in tumor cells to increase the antiglioma efficacy. 
E1A mutant adenovirus Delta-24-RGD (DNX-2401) has shown a favorable toxicity 
profile and remarkable efficacy in a first-in-human phase I clinical trial. However, 
the comprehensive modulation of glioma metabolism in response to Delta-24-RGD 
infection is poorly understood. Integrating mass spectrometry based-quantitative 
proteomics, physical and functional interaction data, and biochemical approaches, 
we conducted a cell-wide study of cytosolic, nuclear, and secreted glioma proteomes 
throughout the early time course of Delta-24-RGD infection. In addition to the severe 
proteostasis impairment detected during the first hours post-infection (hpi), Delta-24-
RGD induces a transient inhibition of signal transducer and activator of transcription 
3 (STAT3), and transcription factor AP-1 (c-JUN) between 3 and 10hpi, increasing 
the nuclear factor kappa B (NF-κB) activity at 6hpi. Furthermore, Delta-24-RGD 
specifically modulates the activation dynamics of protein kinase C (PKC), extracellular 
signal–regulated kinase 1/2 (ERK1/2), and p38 mitogen-activated protein kinase 
(p38 MAPK) pathways early in infection. At extracellular level, Delta-24-RGD triggers 
a time –dependent dynamic production of multitasking cytokines, and chemotactic 
factors, suggesting potential pleiotropic effects on the immune system reactivation. 
Taken together, these data help us to understand the mechanisms used by Delta-
24-RGD to exploit glioma proteome organization. Further mining of this proteomic 
resource may enable design and engineering complementary adenoviral based-vectors 
to increase the specificity and potency against glioma.
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INTRODUCTION
Glioblastoma multiforme (GBM) is the most 
common and aggressive type of malignant glioma, 
characterized by infiltrative growth that cause progressive 
neurologic dysfunction [1]. The standard treatment confers 
the patients a median overall survival time of 15 months 
[2], due to tumor cells that survive initial chemo- and 
radiotherapy causing tumor regrowth/recurrence. Thus, it 
is critical that the development of new therapies or the 
improvement of actual drugs have a positive impact on the 
course of this aggressive disease.
A great effort is devoted to understanding 
the biology of glioma cells to develop treatment 
strategies against their molecular defects [3]. One of 
these approaches is oncolytic virotherapy, which uses 
replication-competent viruses to destroy cancer cells [4, 
5]. Oncolytic adenoviruses are being modified to exploit 
the aberrant expression of proteins in tumor cells to 
enhance tumor tropism and glioma-selective replication 
[6]. In particular, two stable genetic changes in the 
adenovirus genome were engineered, originating the 
E1A mutant adenovirus Delta-24-RGD, that replicates 
selectively in retinoblastoma (Rb) pathway deficient cells 
and infects tumor cells efficiently [7–9]. In general, results 
from pre-clinical and clinical studies have indicated that 
the adenovirus Delta-24-RGD is particularly attractive for 
malignant gliomas [9–13]. In addition, the combination of 
Delta-24-RGD with chemotherapy produced synergistic 
anti-glioma effects [14–16]. Interestingly, a recent clinical 
trial of Delta-24-RGD in patients with glioblastoma 
demonstrated favorable toxicity profile and remarkable 
clinical efficacy [17, 18]. So far, other trials for Delta-
24-RGD (DNX-2401) in combination with IFN-gamma, 
temozolomide or anti-PD1 antibody are currently active 
(Clinical-Trials.gov identifiers NCT02197169, and 
NCT02798406).
It is well known that for an efficient cell lysis 
and adenoviral spread, Delta-24-RGD induces massive 
autophagy [19–22], a late response specifically 
regulated, in part, by the C-Jun N terminal kinases [23]. 
Understanding the cellular mechanisms that orchestrate 
the glioma cell response to oncolytic Delta-24-RGD 
virus will aid to develop novel vectors with enhanced 
capability to release viral progeny and, as a result, to 
elicit a more potent oncolytic effect. One of the potential 
avenues to increasing Delta-24-RGD potency that remains 
understudied is the monitoring of cellular intermediates 
underlying the glioma cell response prior to the activation 
of the autophagic process. In order to characterize the 
missing links in the biochemical understanding of the 
signaling pathways impaired in glioma cells during 
early phases of Delta-24-RGD infection, we have used 
a discovery platform combining a subcellular mass 
spectrometry based-quantitative proteomics approach, 
physical and functional interaction data, and biochemical 
approaches. The integration of these data will allow us 
to uncover means by which the molecular pathways are 
chronologically regulated during Delta-24-RGD infection 
at early time points.
RESULTS
Characterization of the early proteostasis 
impairment induced by Delta-24-RGD infection 
in glioma cells
To analyze the early proteostasis imbalance induced 
by Delta-24-RGD, cytosolic and nuclear subcellular 
fractions were isolated from mock and U87-infected cells 
(6 and 10hpi). Two complementary proteome quantitation 
methods were used to monitor both protein localization and 
abundance within cytosol and nucleus during early phases 
of Delta-24-RGD infection (Figure 1). Detection of Serine/
threonine-protein kinase OSR1, mitochondrial prohibitin, 
and GAPDH preferentially in the cytosolic fraction, in 
addition to major dimethylated histone H3 location in the 
nuclear fraction indicated the efficiency of the enrichment 
procedure (Figure 2). Among cytosolic and nuclear proteins 
consistently quantified during the time course (Figure 3A 
and 3B), 324 proteins tend to be differentially expressed 
between Mock and glioma-infected cells (Figure 3C, and 
Supplementary Tables 1 and 2). Proteome-wide exploration 
revealed that 202 protein products are differentially 
expressed at 6hpi, increasing the proteome alterations as 
the infection progresses (286 differential proteins at 10hpi) 
(Figure 3B, and Supplementary Figure 1). The most up-, 
and down-regulated proteins in both compartments are 
shown in Table 1. As shown in Figure 3B, minor cytosolic 
alterations were observed at 6 and 10hpi, whereas most 
changes in protein abundance were observed at nuclear 
level (Supplementary Figure 1). This was expected, as 
during adenovirus infection, there are severe structural and 
functional alterations in the nucleus of the host cell [24–26]. 
One of the most overexpressed protein in response to Delta-
24-RGD infection is the Non-POU domain-containing 
octamer-binding protein (NONO). Modulation of NONO 
expression during Delta-24-RGD infection was verified by 
Western blotting in nuclear extracts and in total cell extracts 
(Supplementary Figure 2), confirming the increment of this 
transcriptional regulator during the infection, and partially 
validating the quantitative LC-MS/MS approach used in 
this study. Interestingly, subcellular distribution analysis 
of the glioma cell proteome modified by Delta-24-RGD 
also reveal an early alteration of protein components of 
adherents junctions and extracellular vesicles (Figure 3D).
Functional modules progressively disrupted in 
Delta-24-RGD-infected glioma cells
To explore the cooperative action among 
differentially modulated proteins by Delta-24-RGD, we 
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performed protein-scale interaction networks merging 
the cellular targets that tend to be de-regulated during 
infection. Protein interactome networks were constructed 
using IPA software. The integrative network-based 
workflow allowed to: i) decipher the molecular context 
of the cellular targets deregulated in each time point, ii) 
establish a framework to monitor potential interaction 
between deregulated targets and network modules 
during infection, and iii) to determine causal regulators 
of the time-dependent networks that may be considered 
as protein targets to modulate the infectivity process in 
glioma cells. Based on the altered common proteome 
between 6 and 10hpi (148 differentially expressed protein 
products) (Figure 3C), protein-interactome networks 
revealed that Delta-24-RGD mainly impacts on specific 
canonical pathways like RAN signaling (p-val: 2,08E-
6), cell cycle control of chromosomal replication (p-val: 
2,99E-6), and EIF2 signaling (p-val: 7,6E-10) (Figure 
4A), indicating a progressive imbalance in the nucleo-
cytoplasmic transport through the nuclear pore complex 
(NPC), and readjustments in DNA replication (p-val: 2,7E-
8), transcription (p-val:7,7E-7), and mRNA translation 
(p-val: 4,1E-11) between 6 and 10hpi (Supplementary 
Figure 3). Moreover, protein clusters involved in cellular 
adhesion and differentiation was compromised at 6hpi 
(Figure 4B). In addition, our data pointed out a time-
dependent deregulation of specific biological processes 
(Figure 4B). Protein clusters involved in RNA processing 
and proliferation/cell death pathways were mapped across 
both time points, while protein groups involved in cell 
cycle arrest, generation of ROS, and antiviral response 
were exclusively detected at 10hpi. (Figure 4B).
Early temporal dynamics of STAT3, cJUN, 
NFκB and protein kinase C signaling pathways 
in glioma-infected cells
We wanted to decipher which biological activities 
were occurring that may be responsible for protein 
expression changes induced by Delta-24-RGD. The 
predictive analysis of upstream modulation suggested 
potential impairment of upstream regulators such as 
STAT3, and JUN during the early stages of Delta-24-
RGD (Figure 5A). Further experiments were performed 
Figure 1: Hybrid proteomic approach to define spatial-temporal changes in organelle proteomes throughout Delta-
24-RGD Infection. 
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to monitor the temporal activation profile of both 
transcription factors during the first ten hours of infection. 
As shown in Figure 5B, a transient inhibition of STAT3 
and c-JUN was detected at 3 and 10hpi, maintaining 
normal activation levels at 6hpi. Moreover, signaling 
modulators like PKC, and NFκB appeared functionally 
interconnected in protein interactome networks modulated 
by Delta-24-RGD (Figure 6). Although changes in their 
expression were not detected in our proteome-wide 
analysis, the alteration of some of their targets may be 
compatible with a dysregulation of their functionality 
during early phases of Delta-24-RGD infection. As shown 
in Figure 6A, an increment in the phosphorylation of serine 
536 of NFκB was specifically detected at 6hpi, suggesting 
a transient activation of NFκB. In addition, Western-blot 
using a specific antibody against phosphorylated PKC 
isoforms (at a residue homologous to activated Thr514 of 
human PKCγ) showed an increase in the activation state 
of PKC at 6hpi, probably due to a slight increment in total 
steady state levels, whereas total PKC levels significantly 
decreased at 10hpi (Figure 6B).
Selectivity of Delta-24-RGD on the interference 
with specific survival routes
To deeply check the effects of Delta-24-RGD 
virus in the modulation of survival potential of glioma 
cells, a signaling pathway analysis was performed 
based on the glioma targets differentially expressed 
upon Delta-24-RGD infection. As shown in Figure 7, 
protein clusters involved in mTOR and EIF2 signaling 
were clearly mapped in both time points. The activation 
Figure 2: Validation of our enrichment procedure. (A) Cytosolic and nuclear fractions resolved by SDS-PAGE electrophoresis. As 
shown in the upper panel, cytosolic and nuclear proteomes differ in the band profiles. (B) Specificity analysis by Western-blotting against 
specific cytosolic proteins (OXSR1, GAPDH), mitochondrial marker (Prohibitin-1) and nuclear histone (dimethyl-lysine 9 of histone H3).
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Table 1: Top differentially expressed proteins during Delta-24RGD infection





p-value Gene name Protein Fold-
change p-value
F2 Prothrombin 0.31 0.015 HIST1H4A Histone H4 0.35 0.005
SSRP1 FACT complex subunit 
SSRP1
0.32 0.026 H3F3B Histone H3 (Fragment) 0.40 0.001
SUPT16H FACT complex subunit 
SPT16
0.34 0.007 HIST1H1E Histone H1.4 0.42 0.002
SCAF1 Splicing factor, arginine/
serine-rich 19
0.35 0.017 HIST1H1B Histone H1.5 0.46 0.010
MTA1 Metastasis-associated 
protein MTA1
0.36 0.044 HIST1H2BK Histone H2B type 1-K 0.47 0.003
HIST1H1C Histone H1.2 0.36 0.040 ERH Enhancer of rudimentary 
homolog
0.64 0.023




H2AFY Core histone macro-H2A.1 0.39 0.027 H2AFV Histone H2A.V 0.65 0.043
RSL24D1 Probable ribosome 
biogenesis protein RLP24
0.43 0.016 SFPQ Splicing factor, proline- and 
glutamine-rich
0.69 0.002
UBTF Nucleolar transcription 
factor 1
0.43 0.013 SQRDL Sulfide:quinone 
oxidoreductase, mitochondrial
0.69 0.026
RFC2 Replication factor C 
subunit 2
2.73 0.012 PSMD9 26S proteasome non-ATPase 
regulatory subunit 9
1.33 0.038
EIF3E Eukaryotic translation 
initiation factor 3 subunit E
2.87 0.007 HDGF Hepatoma-derived growth 
factor
1.37 0.025
EIF3L Eukaryotic translation 
initiation factor 3 subunit L
2.93 0.030 TOMM70 Mitochondrial import receptor 
subunit TOM70
1.43 0.043
ARID2 AT-rich interactive 
domain-containing protein 
2
3.03 0.047 SNX6 Sorting nexin 6, isoform 
CRA_b
1.52 0.007
EIF3H Eukaryotic translation 
initiation factor 3 subunit 
H
3.07 0.044 A2M Alpha-2-macroglobulin 1.59 0.006
RACK1 Receptor of activated 
protein C kinase 1
3.08 0.002 LTF Lactotransferrin 1.86 0.001
G3BP1 Ras GTPase-activating 
protein-binding protein 1
3.14 0.000 NASP Nuclear autoantigenic sperm 
protein
3.18 0.010
CPSF7 Cleavage and 
polyadenylation-specificity 
factor subunit 7






















processing protein 7 
homolog A
0.25 0.022 HIST1H2BK Histone H2B type 1-K 0.49 0.004
HIST1H1C Histone H1.2 0.28 0.006 HIST1H4A Histone H4 0.32 0.015
F2 Prothrombin 0.31 0.032 H3F3B Histone H3 (Fragment) 0.35 0.010
H2AFY Core histone macro-H2A.1 0.32 0.001 HIST1H1E Histone H1.4 0.47 0.024
SCAF1 Splicing factor, arginine/
serine-rich 19
0.34 0.043 HIST1H1B Histone H1.5 0.48 0.036
ARPC4 Actin-related protein 2/3 
complex subunit 4




IMP3 U3 small nucleolar 
ribonucleoprotein protein 
IMP3
0.36 0.007 SERPINE1 Plasminogen activator 
inhibitor 1
0.60 0.003
NUP50 Nuclear pore complex 
protein Nup50
0.38 0.025 AKAP2 A-kinase anchor protein 2 0.62 0.012
UTP6 U3 small nucleolar 
RNA-associated protein 6 
homolog
0.38 0.016 SUPT16H FACT complex subunit 
SPT16
0.63 0.010
SSRP1 FACT complex subunit 
SSRP1






3.12 0.003 RPL23 60S ribosomal protein L23 1.31 0.015
RRBP1 Ribosome-binding protein 
1






3.51 0.016 KYNU Kynureninase 1.40 0.035
RACK1 Receptor of activated 
protein C kinase 1
3.52 0.000 A2M Alpha-2-macroglobulin 1.43 0.022
ANXA2 Annexin A2 3.56 0.011 RPN2 Dolichyl-
diphosphooligosaccharide-
prot. glycosyltransf. sub. 2
1.45 0.003
RFC2 Replication factor C 
subunit 2
3.69 0.008 CNDP2 Cytosolic non-specific 
dipeptidase
1.46 0.029
ARID2 AT-rich interactive 
domain-containing protein 
2
4.33 0.042 PSMD9 26S proteasome non-ATPase 
regulatory subunit 9
1.55 0.021
EIF3F Eukaryotic translation 
initiation factor 3 subunit F
4.58 0.038 HDGF Hepatoma-derived growth 
factor
1.65 0.033
PDCD6 Programmed cell death 
protein 6
4.93 0.014 LETM1 LETM1 and EF-hand domain-
containing protein 1
2.73 0.003
RPS15 40S ribosomal protein S15 6.43 0.032 NASP Nuclear autoantigenic sperm 
protein
3.36 0.026
Differential proteins are ranked from most down-regulated to most up-regulated in both subcellular compartments at 6 and 10 hpi.
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Figure 3: Differentially expressed proteins throughout early phases of Delta-24-RGD Infection. (A) Volcano plots 
representing the fold-change of cytosolic and nuclear identified proteins with associated P values from the pair-wise quantitative comparisons 
of mock vs glioma-infected cells at 6 and 10hpi. In green, very significantly changed proteins (P < 0.01), in yellow, significantly changed 
proteins (P < 0.05) and in blue, unchanged cytosolic and nuclear proteins between the pair-wise comparisons. (B) Spatial-temporal 
differential proteome distribution at 6 and 10hpi. (C) Venn diagram of common and unique differential proteins between infection time-
points. (D) Classification of glioma proteins affected by Delta-24-RGD based on subcellular localization using DAVID tool.
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Figure 4: Functional metrics of the differential proteomic expression profile detected in glioma cells subjected to 
Delta-24-RGD infection. (A) EIF2, MCMs, and RAN protein interactomes modulated by Delta-24-RGD in glioma cells. The up-
regulation of protein intermediates involved in EIF2 signaling (left panel), down-regulation of proteins involved in RAN signaling (right 
panel), and over-expression of minichromosome maintenance (MCM) protein complex (right panel) are highlighted in both interactomes. 
The alteration in these pathways were detected at 6 and 10hpi. In green, proteins that were down-regulated; In red, proteins that were up-
regulated in our data set. (B) Data-mining of the differential glioma proteome exclusively characterized at 6 or 10hpi. Biological processes 
and biofunctions modulated by Delta-24-RGD at 6 an 10hpi are shown.
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of both pathways has been previously characterized in 
adenoviral infections [27]. However, our bioinformatic 
workflow also predicted a plethora of signaling routes 
that may be potentially compromised during the first 
hours of infection. The activation status of specific 
survival pathways was monitored over time in infected-
glioma cells. During the first 10hpi, no activation waves 
were detected in the kinase activity measurements 
of phospholipase C gamma (PLC-gamma), protein 
kinase B (AKT), stress-activated protein kinase/Jun-
amino terminal kinase (SAPK/JNK), phosphoinositide-
dependent protein kinase 1 (PDK1), and protein kinase A 
(PKA) (Supplementary Figure 4). However, p38MAPK 
activity was diminished at 10hpi, while the activation of 
ERK1/2 was compromised in a time-dependent manner 
(Figure 8). These data pointed out that Delta-24RGD 
specifically targets MAPK and p38 MAPK pathways 
during the first hours post-infection.
Delta-24-RGD alters the glioma secretome: time-
dependent production of specific cytokine subsets
In our attempt to decipher the early metabolic 
response of glioma cells during the Delta-24-RGD 
infection, we have performed a complementary secretome 
analysis of glioma cells during Delta-24-RGD infection. 
Considering that the monitorization of cytokines and 
growth factors secreted by glioma cells to the tumor 
Figure 5: Activation profiling of STAT3 and c-JUN during Delta 24-RGD infection. (A) Upstream regulators proposed 
by IPA software. (B) Levels and residue-specific phosphorylation of STAT3 and c-JUN at 3, 6, and 10hpi. Equal loading of the gels 
was assessed by Ponceau staining and hybridization with a GAPDH specific antibody. Representative Western blot images from three 
independent experiments are shown. Data are presented as mean ± SEM. *P < 0.05 vs mock-infected cells.
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Figure 6: Delta 24-RGD modulates NFκB and PKC activity in early stages of infection. (A) A cluster of NFkB target proteins 
displayed differentialexpression pattern at 6hpi, suggesting the impairment of this essential transcription factor. Activation of NFkB was 
furtherconfirmed by the increase of S536 phosphorylated levels at 6hpi. (B) PKC appeared as a main hub in the functional interactome 
derived from differential expressed proteome at 10hpi. A specific decrease in total PKC levels was evidenced by western-blotting at 10hpi. 
Equal loading of the gels was assessed by Ponceau staining and hybridization with a GAPDH specific antibody. Histograms of band 
densities derived from three independent experiments. Data are presented as mean ± SEM. *P < 0.05 vs mock-infected condition. In green, 
proteins that were down-regulated; In red, proteins that were up-regulated in our data set.
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microenvironment may provide new insights into the 
early modulation of the immune response induced by the 
oncolytic Delta-24-RGD vector, circulating inflammatory 
cytokines and growth factors were analyzed in the cell 
media of Delta-24-RGD-infected cells. Among the 
80 secreted cell–cell signaling molecules analyzed 
(Supplementary Figure 6), 23 were significantly 
increased in the secretome of infected-glioma cells in 
a time-dependent manner (Figure 9). Cytokines and 
growth factors like neurotrophin-3 (NT-3), endothelial 
growth factor (EGF), IL-1beta, and glial cell-derived 
neurotrophic factor (GDNF) were specifically increased 
at 3hpi, while eotaxin was overproduced at 3 and 6hpi 
(Figure 9A). Moreover, the increment in the secretion 
of Rantes (CCL5), leukemia inhibitor factor (LIF), and 
IL-15 was evidenced between 3 and 10hpi (Figure 9B). 
Chemotactic factors like MIP-1delta (CCL15), eotaxin-3, 
MDC (CCL22), and IP-10, together with TNF-beta, TGF-
beta3, Flt3 (CD135), and multitasking cytokines such as 
IL13 and Placental growth factor (PlGF) were upregulated 
in the secretome from Delta-24-RGD-infected cells at 
6hpi (Figure 9C). At 10hpi, an increment in the levels of 
a panel of pleiotropic cytokines (SDF1, GCP-2, MIP-3 
alpha, GCSF, IL-2, and angiogenin) was also significantly 
detected (Figure 9D). Interestingly, these data pointed 
out that Delta-24-RGD triggers a dynamic production 
of pleiotropic factors to the extracellular environment, 
suggesting that these secreted molecules may regulate the 
glioma growth, and differentiation states together with 
the inflammatory cell recruitment and activation in vivo. 
To explore the cooperative action among differentially 
intracellular and extracellular molecules induced by 
Delta-24-RGD, we have performed additional pathway 
analysis merging the proteomic datasets and the secretome 
information. As shown in Table 2, several common altered 
pathways were detected at both time points, although 
differential protein intermediates were different. Most 
of them are related with cell communication, immune 
system, and infection response.
DISCUSSION
We consider that a quantitative knowledge of the 
intracellular and extracellular glioma proteomes may 
help to understand the early effects that occur during 
Delta-24-RGD infection, providing potential therapeutic 
targets that may enhance the efficacy of the adenoviral 
therapy. One of our goals was to generate extensive 
data on the functional groups of glioma proteins early 
deregulated during Delta-24-RGD infection. For that, 
Figure 7: Protein clusters mapped into signaling pathways during Delta 24-RGD infection
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we have applied a system biology approach performing 
different molecular networks and protein profiling analysis 
to identify biologically relevant pathways from large-
scale glioma proteome data. From a functional point of 
view, specific proteomic fingerprints were dynamically 
modulated in a time-dependent manner early in infection. 
Interestingly, our results partially overlapped to those of 
a recent proteogenomic analysis in cervical tumor cells 
infected with wild-type adenovirus serotype 5 (Ad5) in 
similar infectivity conditions [28], partially validating 
our proteomic approach (Supplementary Figure 5), and 
typifying common molecular mechanisms associated 
to the infection of tumor cells with an Ad5 infection. 
STAT3 is a critical mediator of tumorigenesis, and tumor 
progression in glioblastoma [29, 30]. Interestingly, 
Delta-24-RGD inhibits the activity of STAT3 at 10hpi. 
Previous studies have demonstrated that the specific 
blocking of STAT3 produced by oncolytic adenoviral 
mutants induces a potent antitumoral activity in different 
tumoral backgrounds [31, 32]. In line with these findings, 
the STAT3 inhibition may positively contribute to the 
antitumoral effect induced by Delta-24-RGD. The 
activation of NF-κB has been associated with resistance to 
different cell death strategies in GBM, and NF-κB-target 
genes (citokines, cell-cycle regulators, and anti-apoptotic 
proteins between others) have been proposed to influence 
the invasion capacity and resistance to chemotherapy [33]. 
Furthermore, previous studies point out that adenovirus 
infection induces the activation of NF-κB in non-tumoral 
cells [34–36], and also in cancer cell lines [37, 38]. It 
has been shown that inhibition of NF-κB enhanced the 
cytotoxicity of oncolytic adenovirus in ovarian and 
colorectal carcinoma cell lines [37], whereas some 
replication-competent adenoviral vectors strongly reduced 
NF-κB activity, enhancing apoptosis in esophageal 
cancer cells [39]. Therefore, it may be hypothesized 
that the potential transient NF-κB activation observed in 
Delta-24-RGD-infected glioma cells may be explained 
not only by the infection itself, but also as a protection 
mechanism induced by glioma cells to counteract the 
deleterious effects on glioma metabolism caused by 
Delta-24-RGD infection. It is important to note that the 
activation profiling of NF-κB protein clusters is extremely 
complex, being highly dependent on the biological 
context/stimuli [40], and many post-translational 
modifications (PTMs) have been characterized 
(see http://www.uniprot.org/uniprot/Q04206), being still 
unclear how the tangled crosstalk between all PTMs 
regulates the ability of NF-κB proteins to induce or to 
repress defined target genes upon adenoviral infections. 
Figure 8: Signaling pathways disrupted in glioma cells upon Delta 24-RGD infection. Levels and residue-specific 
phosphorylation of p38 MAPK (A), and ERK1/2 (B), in glioma-infected cells. Equal loading of the gels was assessed by Ponceau staining 
and hybridization with a GAPDH specific antibody. Right panels show histograms of band densities from three independent experiments. 
Data are presented as mean ± SEM. *P < 0.05 vs mock-infected condition.
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c-Jun accumulation is robustly elevated in human glial 
tumors and in glioblastoma cell lines, contributing to the 
malignant properties of the cells [41]. Its transcriptional 
activity is regulated by phosphorylation at Ser63 and Ser73 
[42]. Interestingly, an increased in c-Jun phosphorylation 
(Ser63) has been previously detected in Delta-24-RGD-
infected glioma cells late in infection (24hpi) [23]. 
Although this effect was observed using a higher viral 
load (MOI=50), the early c-Jun inhibition demonstrated 
by the drop of phospho-c-Jun (Ser73) levels at 3 and 
10hpi, suggest that c-Jun phosphoproteome is highly 
dynamic during the adenoviral life cycle, maintaining a 
high activation state at advanced stages, needed for the 
adenoviral-mediated autophagic process [23]. Several 
pathways have been monitored during Delta-24-RGD 
infections [23]. Although Akt is not induced early in 
Delta-24-RGD infection, it has been demonstrated that 
the adenoviral vector increases Akt phosphorylation in 
U87 MG glioma cells at 24-48hpi [23]. Moreover, no 
significant changes in ERK1/2 phosphorylation levels 
were detected in Delta-24-RGD-infected lung fibroblasts 
(16-48hpi) [23]. However, Delta-24-RGD induces a 
time-dependent inactivation of ERK1/2 and a decrease in 
total and phospho-p38 levels during the first hours post-
Figure 9: Delta 24-RGD induces early changes in the extracellular cytokine profiling of glioma cells. A time-dependent 
analysis of 80 cytokines/growth factors was performed in the cell media of mock-infected glioma cells and glioma-infected cells (3, 6, and 
10hpi) using a dot-blot protein array method. Three independent experiments were performed. Specific increments in cytokine production 
between 3 and 10 hpi are shown (A-D). Data are presented as mean ± SEM. *p < 0.05, **p<0.01, and ***p<0.001 vs mock-infected condition.
Oncotarget31058www.oncotarget.com
Table 2: Pathway mapping of intracellular deregulated proteins and the differential secretome
PATHWAY PROTEINS (6hpi) PROTEINS (10hpi)
Dendritic Cell Maturation LTA, COL1A1 IL15, COL1A1
CXCR4 Signaling CXCL12, RACK1, GNB2 MYL6, CXCL12, RACK1
CCR5 Signaling in Macrophages CCL5, RACK1, GNB2 CCL5, RACK1
ERK5 Signaling LIF, YWHAB YWHAG, LIF
Glucocorticoid Receptor Signaling A2M, TAF15, TGFB3, HSPA1A/
HSPA1B, CCL5, ARID2, SERPINE1, 
CCL11, IL13, SMARCC2, KRT9, 
KRT14
A2M, IL2, CCL5, ARID2, 
SERPINE1, HSP90AB1, KRT14
Axonal Guidance Signaling CXCL12, CDC42, RACK1, ITGA3, 
RAC2, GNB2
MYL6, CXCL12, CDC42, ACTR2, 
RACK1, ITGA3, ARPC5L, RAC2, 
ARPC1A
Crosstalk between Dendritic Cells and 
Natural Killer Cells
TLN1, ACTG1, LTA IL2, IL15, ACTG1
Leukocyte Extravasation Signaling CXCL12, CDC42, ACTG1, ITGA3, 
RAC2
MYL6, CXCL12, CDC42, ACTG1, 
ITGA3, RAC2
Granulocyte Adhesion and Diapedesis CXCL12, CCL26, CCL22, CCL5, 
ITGA3, CXCL10, CCL15, CCL11
CXCL6, CXCL12, CCL5, ITGA3, 
CCL20, CSF3
Agranulocyte Adhesion and Diapedesis CXCL12, CCL26, CCL22, ACTG1, 
CCL5, ITGA3, CXCL10, CCL15, 
CCL11
CXCL6, MYL6, CXCL12, ACTG1, 
CCL5, ITGA3, CCL20
Ephrin B Signaling CXCL12, CDC42, RACK1, RAC2, 
GNB2
CXCL12, CDC42, RACK1, RAC2
Ephrin Receptor Signaling CXCL12, CDC42, RACK1, ITGA3, 
RAC2, GNB2
CXCL12, CDC42, ACTR2, RACK1, 
ITGA3, ARPC5L, RAC2, ARPC1A
Antiproliferative Role of TOB in T Cell 
Signaling
TGFB3, PABPC1, PABPC4 IL2, PABPC1, PABPC4
HMGB1 Signaling TGFB3, CDC42, LTA, LIF, 
SERPINE1, IL13
IL2, CDC42, LIF, SERPINE1
Wnt/β-catenin Signaling TGFB3, RPS27A
Aryl Hydrocarbon Receptor Signaling TGFB3, MCM7
p38 MAPK Signaling TGFB3, H3F3A/H3F3B
Fc Epsilon RI Signaling IL13, RAC2
Cell Cycle: G1/S Checkpoint Regulation TGFB3, PA2G4
Pancreatic Adenocarcinoma Signaling TGFB3, CDC42, PA2G4
RAR Activation TGFB3, PML, ARID2, SMARCC2
TGF-β Signaling TGFB3, CDC42, SERPINE1
Cyclins and Cell Cycle Regulation TGFB3, PA2G4, CDK1
CCR3 Signaling in Eosinophils CCL26, RACK1, CCL11, GNB2
Protein Kinase A Signaling HIST1H1C, TGFB3, RACK1, 
H3F3A/H3F3B, HIST1H1E, 
HIST1H1B, YWHAB, GNB2
Tight Junction Signaling CSTF3, TGFB3, CDC42, CSTF2, 
ACTG1, CPSF1, CPSF2, NUDT21
PKCθ Signaling in T Lymphocytes IL2, RAC2
Telomerase Signaling IL2, HSP90AB1
CD28 Signaling in T Helper Cells IL2, CDC42, ACTR2, ARPC5L, 
ARPC1A
Recognition of Bacteria and Viruses EIF2S1, IL2, CCL5, LIF
Cytokines and growth factors deregulated at extracellular level during Delta-24RGD infection were jointly analyzed with intracellular 
deregulated proteins. Pathways represented at 6 and 10hpi by IPA software are shown.
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infection in glioma cells. It has been clearly demonstrated 
that adenovirus vectors induce an early ERK1/2 and p38 
activation during cell entry in nontransformed kidney 
cells, although the activation of ERK may differ between 
cell types [43]. Moreover, the constitutively activated 
ERK is one of the key tumorigenic effectors present in the 
majority of glioblastoma variants [44], and its signaling 
is involved in migration and invasion [45]. In fact, 
blocking ERK activity reduces glioma tumorigenicity, 
and even sensitizes to chemotherapy [46, 47], suggesting 
that Delta-24-RGD-induced ERK inactivation may 
be a positive molecular event in the synergistic anti-
glioma effects previously observed in the combination 
of Delta-24-RGD with chemotherapy [14–16]. Like 
ERK, p38 MAPK is upregulated and activated in GBM, 
contributing to tumor invasion and metastasis [48, 49]. 
Its inhibition sensitizes GBM cells to cytotoxic therapy 
and enhances the immune response [48, 50]. Therefore, 
it may be hypothesized that Delta-24-RGD compromises 
the glioma cell survival potential through the attenuation 
of ERK1/2 and p38 MAPK signaling. In contrast, an 
increment in phosphorylated PKC isoforms was detected 
early in Delta-24-RGD infection. Interestingly, PKC has 
been shown to play a critical role in the cellular entry of 
viruses [51]. Although PKC activity has been related to the 
growth regulation of malignant gliomas [52, 53], our data 
suggest that PKC activation may be a viral-induced signal 
to guarantee the adenoviral early gene expression [51]. 
However, the tangled regulatory mechanisms that govern 
the PKC signaling needs further exploration, in order to 
elucidate the specific role of each PKC isoform during 
initial stages of Delta-24-RGD infection.
It has been recently proposed that the immune 
system plays a pivotal role in the therapeutic efficacy 
of oncolytic Delta-24-RGD therapy of glioma [54, 
55]. The induction of the chemokine IP-10 through 
capsid dependent activation of NF-κB by recombinant 
adenoviruses, represents an important early step in the 
development of host immunity against these vectors [43, 
56]. Delta-24-RGD tends to induce the expression of 
IP-10, together with macrophage inflammatory proteins 
(MIPs), and IL-1beta in brains derived from mice bearing 
intracranial glioma tumors [54]. This induction has been 
related to the attraction of macrophages, CD4+ and 
CD8+ T-cells to the tumors [12, 54]. In line with these 
findings, an overproduction of IP-10, IL-1beta, MIP-
1 delta and -3 alpha was also detected in the secretome 
of glioma-infected cells. Interestingly, a panel of other 
chemoattractant factors and multitasking cytokines has 
been unveiled in our study in response to Delta-24-RGD 
treatment. Therefore, it may be hypothesized that the 
secretion of cytokines like Rantes, PIGF, SDF1, IL-2 and 
IL-15 by Delta-24-RGD-infected glioma cells might shed 
new light to the proliferation and influx of immune cells 
recently observed in glioma tumors treated with Delta-24-
RGD-based oncolytic adenovirus [57].
MATERIALS AND METHODS
Materials
The following reagents and materials were used: 
anti-GAPDH (Calbiochem), Anti-OXSR1, anti-NONO 
(Abcam), anti-Prohibitin-1 (cell signaling), anti-
dimethylated histone H3 (Lys9) (Upstate), anti-p38 
MAP kinase, anti-phospho p38 MAP kinase (Thr180/
Tyr 182), anti-PDK1, anti-phospho PDK1 (S241), anti-
PKC-Pan, anti-phospho PKC-pan (T514), anti-pAkt 
(Ser473), anti-Akt, anti-pERK1/2 (Thr202/Tyr204), 
anti-ERK1/2, anti-STAT3, anti-phospho STAT3 (Y705), 
anti-cJUN, anti-phospho cJUN (S73), anti-NF-κB p65, 
anti-NF-κB phospho-p65 (S536), anti-PLCgamma, anti-
phospho PLCgamma (Y783), anti-SAPK/JNK, and anti-
phospho SAPK/JNK (T183/Y185) (Cell Signaling). 
Electrophoresis reagents were purchased from Bio-rad 
and trypsin from Promega.
Virus production, culture and treatment of 
malignant glioma cells
The construction of Delta-24-RGD has been 
previously described [8, 9]. U87 MG glioma cells (ATCC: 
HTB-14) were cultured in DMEM/F12-GlutaMAX (Gibco 
10565018) supplemented with 10% FBS, and 1% penicillin/
streptomycin. 3.5x106 U87 MG cells were infected with 
Delta-24-RGD at multiplicity of infection (MOI) of 25. After 
incubation for 30 minutes with DMEM/F12 1% penicillin/
streptomycin at 37 °C, the double of the volume of DMEM/
F12-GlutaMAX (Gibco 10565018) supplemented with 
10% FBS and 1% penicillin and streptomycin was added 
to the previous media. Cells were incubated under the same 
conditions during the indicated periods of time.
Subcellular fractionation
After the indicated periods of time, the media was 
removed and the cells were washed with 1X cold PBS. 
Then, 500μl of NP40 buffer with protease inhibitors was 
added and cells were harvested. After a centrifugation 
step (1 minute, 18000xg, at 4°C), the supernatant was 
collected in a new eppendorf (cytosolic fraction). The 
pellet was washed with PBS and centrifuged for 1 
minute (1 minute, 18000xg, at 4°C). The supernatant was 
discarded. The pellet (nuclear fraction) was resuspended 
in 50μl of lysis buffer (7M urea, 2M thiourea, 50mM 
DTT) and let on ice for 30 minutes, spinning and 
vortexing each 10 minutes. After a sonication step, the 
lysate was centrifuged for 20 minutes at 20000xg at 
15°C. The supernatant was transfer to a new eppendorf 
and the pellet discarded. Protein concentration of both 




A shotgun comparative proteomic analysis of 
cytosolic fractions using iTRAQ (isobaric Tags for 
Relative and Absolute Quantitation) was performed 
[58]. Global experiments were carried out with two/three 
biological replicates in each experimental condition. 
Cytosolic extracts (300 μg) were precipitated with 
methanol/chloroform, and pellets dissolved in 0.5M 
triethylammonium bicarbonate (TEAB), 6M urea. Protein 
quantitation was performed with the Bradford assay kit 
(Bio-Rad). iTRAQ labeling of each sample was performed 
according to the manufacturer’s protocol (Sciex). Briefly, 
a total of 80 μg of protein from each cellular condition 
was reduced with 50 mM tris (2-carboxyethyl) phosphine 
(TCEP) at room temperature for 1 h, and cysteine residues 
were alkylated with 200 mM methylmethanethiosulfonate 
(MMTS) at room temperature for 10 min. Protein 
enzymatic cleavage was carried out with trypsin 
(Promega; 1:50, w/w) at 37 °C for 16 h. Each tryptic 
digest was labelled according to the manufacturer’s 
instructions with one isobaric amine-reactive tags as 
follows: Tag113, Mock-infected U87 cells-1; Tag114, 
Mock-infected U87 cells-2; Tag115, U87-infected cells 
(6hpi)-1; Tag116, U87-infected cells (6hpi)-2; Tag117, 
U87-infected cells (6hpi)-3;Tag118, U87-infected cells 
(10hpi)-1; Tag119, U87-infected cells (10hpi)-2; Tag121, 
U87-infected cells (10hpi)-3. After 2h incubation, the 
set of labelled samples were pooled and evaporated in a 
vacuum centrifuge. To increase the proteome coverage, the 
peptide pool was fractionated by SCX chromatography. 
Briefly the sample was first dissolved in 10mM KH2PO4, 
20% ACN, pH:3, sonicated and centrifuged for 3 minutes 
at 18000xg at RT. The pellet was discarded and the pH 
˂ 3 was adjusted with formic acid (FA). Peptides were 
eluted with KCl at an increasing gradient from 1mM to 
500mM. 8 different fractions were collected. Purification 
and concentration of peptides was performed using C18 
Zip Tip Solid Phase Extraction (Millipore). Then the 
sample was evaporated under vacuum and reconstituted 
into 10μl of 2% acetonitrile, 0.5% FA, 98% MilliQ-H20 
prior to mass spectrometric analysis.
Nuclear proteome analysis
Nuclear extracts from Mock-infected, and 
U87-infected cells (at 6 and 10hpi) were diluted in 
Laemmli sample buffer and loaded into a 1 mm thick 
polyacrylamide gel with a 4% stacking gel casted over a 
12.5% resolving gel. The run was stopped as soon as the 
front entered 3 mm into the resolving gel so that the whole 
proteome became concentrated in the stacking/resolving 
gel interface. Bands were stained with Coomassie Brilliant 
Blue and excised from the gel. Protein enzymatic cleavage 
(15ug) was carried out with trypsin (Promega; 1:20, w/w) 
at 37°C for 16 h as previously described [59]. Purification 
and concentration of peptides was performed using C18 
Zip Tip Solid Phase Extraction (Millipore).
Mass spectrometry
Peptides mixtures were separated by reverse phase 
chromatography using an Eksigent nanoLC ultra 2D 
pump fitted with a 75 μm ID column (Eksigent 0.075 x 
250 mm). Samples were first loaded for desalting and 
concentration into a 0.5 cm length 100 μm ID pre-column 
packed with the same chemistry as the separating column. 
Mobile phases were 100% water 0.1% formic acid (FA) 
(buffer A) and 100% Acetonitrile 0.1% FA (buffer B). 
For cytosolic peptide mixtures (iTRAQ approach), the 
Column gradient was developed in a 135 min two step 
gradient from 5% B to 25% B in 120 min and 25%B to 
70% B in 15 min. Column was equilibrated in 95% B for 
9 min and 5% B for 14 min. In the case of nuclear peptide 
mixtures (label-free approach), the column gradient was 
developed in a 240 min two step gradient from 5% B to 
25% B in 210 min and 25%B to 40% B in 30 min. Column 
was equilibrated in 95% B for 9 min and 5% B for 14 
min. During all processes, precolumn was in line with 
column and flow maintained all along the gradient at 300 
nl/min. Eluting peptides from the column were analyzed 
using a Sciex 5600 Triple-TOF system. Information data 
acquisition was acquired upon a survey scan performed 
in a mass range from 350 m/z up to 1250 m/z in a scan 
time of 250 ms. Top 25-35 peaks were selected for 
fragmentation. For cytosolic peptides mixtures: the 
minimum accumulation time for MS/MS was set to 75 
ms giving a total cycle time of 2.1 s. Product ions were 
scanned in a mass range from 100 m/z up to 1500 m/z 
and excluded for further fragmentation during 15 s. In the 
case of nuclear peptides mixtures: Minimum accumulation 
time for MS/MS was set to 100 ms giving a total cycle 
time of 3.8 s. Product ions were scanned in a mass range 
from 230 m/z up to 1500 m/z and excluded for further 
fragmentation during 15 s. The MS/MS data acquisition 
was performed using Analyst 1.7.1 (Sciex) and spectra 
files were processed through Protein Pilot Software 
(v.5.0.1-Sciex) using Paragon™ algorithm (v.5.0.1) for 
database search [60], Progroup™ for data grouping, and 
searched against the concatenated target-decoy UniProt 
proteome reference database (Human database Proteome 
ID: UP000005640, 70902 proteins, December 2015 plus 
adenovirus HAv5 database UP000004992, 31 proteins, 
September 2016). False discovery rate was performed 
using a non lineal fitting method [61] and displayed 
results were those reporting a 1% Global false discovery 
rate or better. The mass spectrometry proteomics data 
have been deposited to the ProteomeXchange Consortium 
(http://proteomecentral.proteomexchange.org) [62] via 
the PRIDE partner repository with the data set identifiers 
PXD008023 (nuclear data) and PXD008022 (cytosolic 
data).
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Data analysis for cytosolic proteomes
Relative quantification and protein identification were 
performed with the ProteinPilot™ software (version 5.0; 
Sciex) using the Paragon™ algorithm as the search engine. 
The search parameters allowed for cysteine modification 
by MMTS and biological modifications programm in the 
algorithm (i.e. phosphorylations, amidations, semitryptic 
fragments, etc.). Reporter ion intensities were bias corrected 
for the overlapping isotope contributions from the iTRAQ 
tags according to the certificate of analysis provided by 
the reagent manufacturer (Sciex). The peptide and protein 
selection criteria for relative quantitation were performed 
as follows. Only peptides unique for a given protein were 
considered for relative quantitation, excluding those common 
to other isoforms or proteins of the same family. Proteins 
were identified on the basis of having at least one peptide with 
an ion score above 99% confidence. Among the identified 
peptides, some of them were excluded from the quantitative 
analysis for one of the following reasons: (i) The peaks 
corresponding to the iTRAQ labels were not detected; (ii) the 
peptides were identified with low identification confidence 
(<1.0%); (iii) the sum of the signal-to-noise ratio for all of 
the peak pairs was <6 for the peptide ratios. The protein 
sequence coverage (95% conf.) was estimated for specific 
proteins by the percentage of matching amino acids from the 
identified peptides having confidence greater than or equal 
to 95% divided by the total number of amino acids in the 
sequence. Several quantitative estimates provided for each 
protein by ProteinPilot were utilized: the fold change ratios of 
differential expression between labelled protein extracts; the 
p-value, representing the probability that the observed ratio is 
different than 1 by chance. A decoy database search strategy 
was also used to estimate the false discovery rate (FDR), 
defined as the percentage of decoy proteins identified against 
the total protein identification. The FDR was calculated by 
searching the spectra against the decoy database generated 
from the target database. The results were then exported 
into Excel for manual data interpretation. Although relative 
quantification and statistical analysis were provided by the 
ProteinPilot software, an additional 1.3-fold change cutoff 
for all iTRAQ ratios (ratio <0.77 or >1.3) and a p-value 
lower tan 0.05 were selected to classify proteins as up- or 
down-regulated (at least in two of three biological replicates). 
Proteins with iTRAQ ratios below the low range (0.77) were 
considered to be underexpressed, whereas those above the 
high range (1.3) were considered to be overexpressed.
Data analysis for nuclear proteomes
The peptide quantification was performed using 
the Progenesis LC−MS software (ver. 2.0.5556.29015, 
Nonlinear Dynamics). Using the accurate mass 
measurements from full survey scans in the TOF detector 
and the observed retention times, runs were aligned to 
compensate for between-run variations in our nanoLC 
separation system. To this end, all runs were aligned to a 
reference run automatically chosen by the software, and a 
master list of features considering m/z values and retention 
times was generated. The quality of these alignments 
was manually supervised with the help of quality scores 
provided by the software. The peptide identifications were 
exported from Protein Pilot software and imported in 
Progenesis LC− MS software where they were matched 
to the respective features. Output data files were managed 
for subsequent statistical analyses and representation. 
Proteins identified by site (identification based only on 
a modification), reverse proteins (identified by decoy 
database) and potential contaminants were filtered out. 
Proteins quantified with at least two unique peptides, a 
T-test p-value lower than 0.05, and an absolute fold change 
of <0.77 (down-regulation) or >1.3 (up-regulation) in linear 
scale were considered significantly differentially expressed.
Bioinformatics
The proteomic data were analyzed using QIAGEN’s 
Ingenuity® Pathway Analysis (IPA) (QIAGEN Redwood 
City, www.qiagen.com/ingenuity), to detect and infer 
differentially activated/deactivated pathways because of 
Delta-24RGD treatment. This software comprises curated 
information from databases of experimental and predictive 
origin, enabling discovery of highly represented functions, 
pathways, and interactome networks. The IPA comparison 
analysis considers the signalling pathway rank according 
to the calculated p-value and reports it hierarchically. The 
software generates significance values (p-values) between 
each biological or molecular event and the imported 
molecules based on the Fisher’s exact test (p ≤ 0.05).
Secretome analysis
A dot-blot protein array was used for cytokine 
profiling (Abcam). Briefly, membranes with 80 cytokine 
antibodies were blocked with the manufacturer’s blocking 
buffer at room temperature (RT) for 30 min, and incubated 
o/n with 1ml of undiluted cell-cultured media from Mock- 
and U87-infected cells (3, 6, and 10hpi) (n=3). After 
washing, a biotinylated anti-cytokine antibody mixture 
was added to the membranes followed by incubation with 
HRP-conjugated streptavidin and then exposed to the 
manufacturer’s peroxidase substrate. Chemiluminescence 
signals were quantified with the ImageQuant ECL system 
(BioRad) and normalized to the background levels and 
positive control signals. The Perseus software (version 
1.5.6.0) was used for statistical analysis [63].
Western-blotting
Equal amounts of protein (10 μg) were resolved 
in 4–15% Criterion™ TGX Stain-Free™ Protein Gels 
(#5678085 Bio-rad). Mock-infected and U87-infected 
protein cell extracts were electrophoretically transferred 
onto nitrocellulose membranes using Trans-Blot Turbo 
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(BioRad) for 7 minutes at 2.5A constant, up to 25V. Equal 
loading of the gels was assessed by stain free digitalization 
and Ponceau staining. Membranes were probed with 
primary antibodies at 1:1000 dilution in 5% nonfat milk 
or BSA. After incubation with the appropriate horseradish 
peroxidase-conjugated secondary antibody (1:5000), 
antibody binding was detected by a Chemidoc™MP 
Imaging System (Bio-Rad) after incubation with an 
enhanced chemiluminescence substrate (Perkin Elmer). All 
Band intensities were measured with Image Lab Software 
Version 5.2 (Bio-Rad) and normalized to GAPDH.
CONCLUSIONS
From a biological point of view, we have partially 
deciphered the molecular events triggered by Delta-24-
RGD prior to the induction of autophagy in glioma cells. 
Moreover, we have established a working pipeline for the 
future monitorization of the intracellular and extracellular 
proteostatic derangements induced by Delta-24-RGD-based 
vectors in pre-clinical glioma models. The high-throughput, 
and straightforward workflow applied in this study has 
allowed us the generation of quantitative molecular maps 
that may be useful to the development of complementary 
adenoviral based-vectors to increase the specificity and 
potency against glioma. Finally, we consider that the 
evaluation of the cytokine panel modulated by Delta-24-
RGD might be of potential clinical interest, with the aim to 
monitoring the immune response elicited by Delta-24-RGD 
treatment in patients that participate in clinical trials where 
this therapeutic vector is being supplied.
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